Faes Farma, S.A.

FAE

ES0134950F36

Pharmaceuticals

Market Closed - BME Other stock markets 11:35:15 2024-05-13 am EDT			After market 03:59:30 pm
3.59 ^EUR	+1.70%		3.59	0.00%

Apr. 26	FAES FARMA : Q1 beat; full-year guidance re-affirmed
Apr. 15	Faes Farma, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Faes Farma, S.A. Reports Earnings Results for the Half Year Ended June 30, 2021

July 28, 2021 at 08:08 am EDT

Faes Farma, S.A. Announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was EUR 192.213 million compared to EUR 201.311 million a year ago. Net income was EUR 47.193 million compared to EUR 45.582 million a year ago. Basic earnings per share from continuing operations was EUR 0.161 compared to EUR 0.163 a year ago.

Latest news about Faes Farma, S.A.

FAES FARMA : Q1 beat; full-year guidance re-affirmed	Apr. 26
Faes Farma, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 14	CI
FAES FARMA : Q4 profitability exceeded expectations	Feb. 27
Faes Farma, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
FAES FARMA : Mixed Q3; markets need more from Faes to be convinced	23-10-25
Faes Farma, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-14	CI
FAES FARMA : A soft Q2, as expected; guidance maintained	23-08-01
Faes Farma, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-28	CI
FAES FARMA : Increased R&D focus and inflationary pressures to hold back near-to-medium term earnings	23-07-12
FAES FARMA : A healthy start to 2023	23-05-08
Faes Farma, S.A. completed the acquisition of NovoSci.	23-05-02	CI
Faes Farma, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-02	CI
FAES FARMA : 2022 guidance met + positive view maintained	23-03-06
Faes Farma, S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
Faes Farma, S.A. agreed to acquire NovoSci.	23-01-11	CI
Roche’s Alzheimer’s failure has sector-wide implications	22-11-14
Faes Farma, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-11-02	CI
FAES FARMA : Soft Q3, but 2022 guidance maintained	22-10-28
FAES FARMA : Another stronger quarter but maintained full-year outlook	22-08-01
Faes Farma, S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-07-28	CI
Faes Farma, S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-07-28	CI
FAES FARMA : Strong Q1; but some moderation lies ahead	22-05-02
Faes Farma, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
FAES FARMA : A strong Q4 sums up a decent 2021	22-03-02
Faes Farma, S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-25	CI

Chart Faes Farma, S.A.

Duration

Period

More charts

Company Profile

Faes Farma SA is a Spain-based company engaged in the pharmaceutical industry. The Company specializes in the research, production, distribution and sale of prescription and generic drugs, over-the-counter (OTC) medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The Companyâs research lines are mainly focused on the development of new drugs for the treatment of allergy, venous insufficiency and irritable bowel syndrome, among others. In addition, it provides animal nutrition products. The Company operates in Spain, Portugal, Chile and Mexico, among others. It controls a number of subsidiaries, such as Laboratorios Vitoria SA, Laboratorios Veris SA, Lazlo International SA, Ingaso Farm SLU, Esfion SA and Biotecnet I MAS D SA.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

FAES FARMA : Q1 beat; full-year guidance re-affirmed

April 26, 2024 at 11:34 am EDT

More Strategies

Ratings for Faes Farma, S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

3.53 EUR

Average target price

3.708 EUR

Spread / Average Target

+5.03%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
FAES FARMA, S.A.	+13.61%	1.18B
ELI LILLY AND COMPANY	+29.98%	684B
NOVO NORDISK A/S	+30.34%	568B
JOHNSON & JOHNSON	-3.52%	361B
MERCK & CO., INC.	+18.59%	329B
ABBVIE INC.	+4.07%	284B
ASTRAZENECA PLC	+16.21%	240B
NOVARTIS AG	+9.66%	208B
ROCHE HOLDING AG	-6.83%	200B
AMGEN INC.	+7.09%	166B

Other Pharmaceuticals

Faes Farma, S.A.

Equities

FAE

ES0134950F36

Pharmaceuticals

Faes Farma, S.A. Reports Earnings Results for the Half Year Ended June 30, 2021

EPS Revisions

Quarterly revenue - Rate of surprise